Date: 2015-06-22
Type of information: Nomination
Compound:
Company: Bind Therapeutics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 22, 2015, Bind Therapeutic announced that Andrew Hirsch has been appointed president and chief executive officer of the Company. Mr. Hirsch had been serving in the role on an acting basis since March 2015. Mr. Hirsch has also been elected to Bind's Board of Directors. "After a thorough evaluation of internal and external candidates, the Board is confident that Andrew is the right person to lead the next phase of the Company's growth," said Daniel Lynch, Chairman, Bind Therapeutics Board of Directors. "His vision, operational philosophy and experience are ideally suited for the position. Since stepping in as acting president and CEO in March, we have been very impressed with his ability to quickly develop, and begin implementing, a strategic plan to drive current and future therapeutic opportunities in a direction we believe will most effectively create products that solve serious medical problems and create value for our shareholders." * On March 10, 2015, Bind Therapeutics announced that Andrew Hirsch has been appointed the acting president and chief executive officer of the Company. Mr. Hirsch was formerly Bind's chief operating officer and chief financial officer and replaces Scott Minick, who will remain a member of BIND's Board of Directors. Bind intends to announce a permanent CEO following an expeditious evaluation of internal and external candidates. Prior to joining Bind, Mr. Hirsch was chief financial officer at Avila Therapeutics until its acquisition by Celgene, in March 2012. Previously, Mr. Hirsch served in roles of increasing responsibility during his nearly 10 year tenure at Biogen Idec, most recently as vice president, Corporate Strategy and M&A, where he played a key role in evaluating new strategies for the company and identifying strategic M&A opportunities. While at Biogen Idec, Mr. Hirsch also served as Program Executive for the Tecfidera development team, leading the successful transition from phase 2 to phase 3 clinical trials. He holds a Masters of Business Administration from the Tuck School at Dartmouth College and a Bachelor of Arts in Economics from the University of Pennsylvania. In connection with Mr. Hirsch's new role, Bind announced the following key new hires, as well as management and organizational changes. Margaret Read has joined Bind as vice president, Biology. In this position, Dr. Read will play a key role in defining strategic direction for the Company's Accurin product portfolio. Dr. Read has worked as a consultant with Bind for the past year and was formerly vice president, Product Development, at Infinity Pharmaceuticals. Prior to Infinity, Dr. Read was director of Cell and Molecular Oncology at Millennium. David Mantus has joined BIND as vice president, Regulatory Affairs and Quality Assurance. Dr. Mantus will be responsible for the development and implementation of Bind's regulatory strategy and lead all interactions with healthcare regulatory authorities. Dr. Mantus was formerly vice president, Regulatory Affairs, at Cubist Pharmaceuticals. Dan Koerwer has been appointed chief business officer. In this capacity, Mr. Koerwer will be responsible for business development, commercialization and program and alliance management. Mr. Koerwer joined Bind in 2010 as head of Business Development and was most recently senior vice president, Business Development and Commercial. In this role, he successfully led the creation of key strategic collaborations with AstraZeneca, Pfizer, Merck, Roche and Amgen. Mr. Koerwer is a member of the executive leadership team.
Hagop Youssoufian, who joined BIND as chief medical officer in 2014, will continue to lead the Company's clinical development programs and will take on added responsibility for Regulatory Affairs and Quality Assurance at Bind in anticipation of advancing BIND-014 into phase 3 pivotal trials. Dr. Youssoufian will continue as a member of Bind's executive leadership team.
Chris Lindblom has been promoted to senior vice president, Finance and Administration. In his new role, he will manage operating performance and financing activities, as well as join the executive leadership team. Mr. Lindblom joined Bind in 2014 as vice president, Finance. He previously worked as vice president of Finance and Treasurer at OvaScience and held roles with increasing responsibilities, including vice president of accounting and financial planning, at Infinity Pharmaceuticals.
Financial terms:
Latest news:
